Medine.co.uk

Pholcodine Linctus Bp

Document: spc-doc_PL 04917-0005 change

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Strong Pholcodine Linctus BP

2.    QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5ml contains Pholcodine BP 10mg

3.    PHARMACEUTICAL FORM

Oral solution: Clear, colourless, raspberry and cola flavoured syrup.

4.    CLINICAL PARTICULARS

4.1.    Therapeutic Indications

Suppression of non-productive cough.

4.2.    Posology and Method of Administration

Adults:    5ml spoonful 3-4 times daily

Children: Not recommended.

4.3.    Contra-Indications

Liver disease, ventilatory failure, asthma, bronchitis, bronchiectasis. Use in patients with hypersensitivity or idiosyncratic response to the active ingredient, use in children.

4.4 Special warnings and precautions for use

Patients with rare hereditary problems of fructose intolerance should not take this medicine.

4.5. Interaction with other Medicinal Products and other Forms of Interaction

Depressant effects may occur with concurrent alcohol ingestion; concurrent (or within 2 weeks) use of MAOIs may lead to excitation; the depressant effects might be increased by phenothiazines, MAOIs and tricyclic antidepressants.

4.6. Pregnancy and Lactation

This product should not be used during pregnancy or lactation unless it is considered essential by the physician.

4.7. Effects on Ability to Drive and Use Machines

Pholcodine may induce drowsiness. Patients receiving this medication should not drive or operate machinery unless it has been shown not to affect mental or physical ability.

4.8 Undesirable effects

Constipation, nausea and drowsiness occasionally occur.

Immune system disorders: hypersensitivity reactions, anaphylaxis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9. Overdose

Restlessness, excitement and ataxia may occur after large doses. A toxic dose in children is reported to be about 200mg.

Treatment: Gastric lavage with supportive and symptomatic measures. In severe cases, and where respiratory depression occurs an opioid antagonist such as Naloxone - should be considered.

PHARMACOLOGICAL PROPERTIES

5.


5.1. Pharmacodynamic Properties

Morphine or codeine derivatives. By tradition used mainly as an antitussive. It suppresses the cough reflex by a direct central action, probably in the medulla or pons. It has little or no analgesic or euphorigenic activity.

5.2. Pharmacokinetic Properties

Metabolised in the liver.

5.3. Pre-clinical Safety Data

Not stated.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Citric Acid BP

Sodium Carboxymethylcellulose 7HOF BP

Glycerol BP

Sodium Benzoate BP

Saccharin Sodium BP

Maltitol liquid (E965)

Ethanol 96% BP Raspberry/Cola flavour Purified Water BP to volume

6.2. Incompatibilities

None known.

6.4.


6.5.


6.6.


7.


8.


Amber glass bottles - 2 years

High density polyethylene bottles - 2 years


Special precautions for storage

Store below 20°C. Protect from light.


Nature and content of container

Amber Grade III glass bottle with pilfer proof screw cap, 100ml, 125ml, 200ml and 500ml. Virgin HDPE bottle with tamper evident screw cap, 500ml, 1 Litre and 2 Litres.


Instruction for use and handling

As for all medicines - no special requirements.


MARKETING AUTHORISATION HOLDER

Pinewood Laboratories Ltd.,

Ballymacarbry,

Clonmel,

Co. Tipperary,

Ireland


MARKETING AUTHORISATION NUMBER PL 04917/0005


DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION


DATE OF REVISION OF THE TEXT

10


27/07/2015